Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting

SAN CARLOS, Calif., Oct. 11, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that six abstracts, including one late-breaking abstract highlighting its TIL therapy, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 32^nd Annual Meeting from November 8-12, 2017 in National Harbor, Maryland. 

The late-breaking abstract titles are listed on the conference website at https://www.sitcancer.org/2017/abstracts/titles/late-breaking.

The other SITC abstract titles are listed on the conference website under General Categories at https://www.sitcancer.org/2017/abstracts/titles. The details of the posters are as follows:

Cellular Therapy Approaches Late-Breaking Abstract

Title: Novel cryopreserved tumor infiltrating lymphocytes (LN-144) administered to patients with metastatic melanoma demonstrates efficacy and tolerability in a multicenter Phase 2 clinical trial
Authors: Sarnaik, et al.
Poster #: 515
Presentation date: Friday, November 10, 2017

Cellular Therapy Approaches Abstracts

Title: A Cryopreserved TIL Product, LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes for Adoptive Cell Transfer
Authors: Wardell, et al.
Poster #: 203
Presentation date: Friday, November 10, 2017

Title: Studies of Key Quality Attributes for TIL Product, LN-144
Authors: Ritthipichai, et al.
Poster #: 194
Presentation date: Saturday, November 11, 2017

Immune Modulation, Cytokines, and Antibodies Abstract

Title: The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of
Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
Authors: Frank, et al. 
Poster #: 357
Presentation date: Friday, November 10, 2017

Clinical Trials (In Progress) Abstracts

Title: A Phase 2 study to evaluate the safety and efficacy using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Authors: Leidner, et al.
Poster #: 221
Presentation date: Friday, November 10, 2017

Title: A Phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
Authors: Jazaeri, et al.
Poster #: 220
Presentation date: Saturday, November 11, 2017

About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com. 

Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for its current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and its ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, its product candidates; the strength of Company’s product pipeline; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license or development agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements.  A further list and description of the Company’s risks, uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
[email protected]
[email protected]